Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-08-22 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 85.1 KB | ||
| 2022-08-04 22:32 |
Cellectis publie ses résultats financiers du deuxième trimestre 2022
|
French | 383.4 KB | ||
| 2022-08-04 22:30 |
Cellectis Provides Business Update and Reports Financial Results for Second Qua…
|
English | 242.5 KB | ||
| 2022-08-01 22:30 |
Cellectis reçoit l’accord de la FDA pour démarrer un essai clinique sur UCART20…
|
French | 106.8 KB | ||
| 2022-08-01 22:30 |
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufacture…
|
English | 108.9 KB | ||
| 2022-07-28 22:30 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 71.4 KB | ||
| 2022-07-28 22:30 |
Cellectis to Report Second Quarter 2022 Financial Results
|
English | 55.7 KB | ||
| 2022-06-30 11:20 |
Cellectis dévoile dans Nature Communications de nouvelles cellules CAR T univer…
|
French | 86.8 KB | ||
| 2022-06-30 11:19 |
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Eva…
|
English | 77.5 KB | ||
| 2022-06-28 22:36 |
Cellectis annonce les nominations d'Axel-Sven Malkomes et de Donald A Bergstrom…
|
French | 55.3 KB | ||
| 2022-06-28 22:36 |
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergst…
|
English | 56.8 KB | ||
| 2022-06-28 22:08 |
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis S.A. du 2…
|
French | 38.1 KB | ||
| 2022-06-28 22:08 |
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held o…
|
English | 41.9 KB | ||
| 2022-06-08 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 84.9 KB | ||
| 2022-06-08 22:30 |
Monthly information on share capital and company voting rights
|
English | 77.5 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
